Responses cited increasing workloads, shrinking autonomy, mounting interference from hospital administrators and insurance ...

A group of faith leaders, community advocates, and activists continues to call on the Monroe County District Attorney's ...

The following letter was submitted to The Montana Standard from Butte-Silver Bow Chief Executive J.P. Gallagher. Writing on ...

Hidden narcissists often use this phrase to justify their reactions and avoid accountability, subtly making themselves the ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

The June 22 attack on the Mar Elias Church in Damascus underscores the threat of extremism in Syria even after the fall of ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

The survey also comes as tensions heat up between Israel and Iran and concerns Israel could launch a strike on Tehran's nuclear plants.